DELAFLOXACIN MEGLUMINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H12ClF3N4O4.C7H17NO5
Molecular Weight	635.974
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.NC1=C(F)C=C(F)C(=N1)N2C=C(C(O)=O)C(=O)C3=CC(F)=C(N4CC(O)C4)C(Cl)=C23

InChI

InChIKey=AHJGUEMIZPMAMR-WZTVWXICSA-N

InChI=1S/C18H12ClF3N4O4.C7H17NO5/c19-12-13-7(1-9(20)14(12)25-3-6(27)4-25)15(28)8(18(29)30)5-26(13)17-11(22)2-10(21)16(23)24-17;1-8-2-4(10)6(12)7(13)5(11)3-9/h1-2,5-6,27H,3-4H2,(H2,23,24)(H,29,30);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1

HIDE SMILES / InChI

Molecular Formula	C7H17NO5
Molecular Weight	195.2136
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C18H12ClF3N4O4
Molecular Weight	440.76
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26119479
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/history/baxdela.html http://www.malinplc.com/wp-content/uploads/2015/10/Melinta-Therapeutics-Presents-Complete-Delafloxacin-Results-09.10.15.pdf

Delafloxacin (CAS registry number 189279-58-1) was described as WQ-3034 by Wakunaga Pharmaceutical Co., Ltd., Osaka & Hiroshima, Japan. It was first licensed in 1999 to Abbott Park, IL, and further developed as ABT-492. Delafloxacin (Baxdela), a fluoroquinolone antibiotic, is currently being developed by Melinta Therapeutics. It is a novel investigational fluoroquinolone in development for the treatment of uncomplicated gonorrhea, and acute bacterial skin and skin structure infections. Delafloxacin shows MICs remarkably low against Gram-positive organisms and anaerobes and similar to those of ciprofloxacin against Gram-negative bacteria. It remains active against most fluoroquinolone-resistant strains, except enterococci. Its potency is further increased in acidic environments (found in many infection sites). Delafloxacin is active on staphylococci growing intracellularly or in biofilms. Delafloxacin is a dual-targeting fluoroquinolone, capable of forming cleavable complexes with DNA and topoisomerase IV or DNA gyrase and of inhibiting the activity of these enzymes in both Gram-positive and Gram-negative bacteria. On Oct 24, 2016, Melinta Therapeutics Submitted Baxdela New Drug Application for hospital-treated skin infections.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Haemophilus influenzae 10 Target ID: CHEMBL355 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26119479	Inhibitor 8297
Moraxella catarrhalis 10 Target ID: CHEMBL614429 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26119479	Inhibitor 8297
Neisseria gonorrhoeae 5 Target ID: CHEMBL614430 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26119479	Inhibitor 8297
Klebsiella pneumoniae 2 Target ID: CHEMBL350 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26119479	Inhibitor 8297
Staphylococcus aureus 67 Target ID: CHEMBL352 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22875850	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Community-acquired bacterial pneumonia 11 Sources: https://clinicaltrials.gov/ct2/show/NCT02679573	Curative	Phase III 656	BAXDELA Approved Use BAXDELA is a fluoroquinolone antibacterial indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria. (1.1) To reduce the development of drug-resistant bacteria and maintain the effectiveness of BAXDELA and other antibacterial drugs, BAXDELA should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. (1.2) Launch Date 1.49774402E12
Gonorrhea 30 Sources: https://clinicaltrials.gov/ct2/show/NCT02015637	Curative	Phase III 656	BAXDELA Approved Use BAXDELA is a fluoroquinolone antibacterial indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria. (1.1) To reduce the development of drug-resistant bacteria and maintain the effectiveness of BAXDELA and other antibacterial drugs, BAXDELA should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. (1.2) Launch Date 1.49774402E12
Acute bacterial skin and skin structure infection 16 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208610s000,208611s000lbl.pdf	Curative	Approved 8429	BAXDELA Approved Use BAXDELA is a fluoroquinolone antibacterial indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria. (1.1) To reduce the development of drug-resistant bacteria and maintain the effectiveness of BAXDELA and other antibacterial drugs, BAXDELA should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. (1.2) Launch Date 1.49774402E12

C_max

Value	Dose	Analyte	Population
8.94 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208610s007,208611s006lbl.pdf	300 mg single, intravenous dose: 300 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DELAFLOXACIN MEGLUMINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
7.17 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208610s007,208611s006lbl.pdf	450 mg single, oral dose: 450 mg route of administration: Oral experiment type: SINGLE co-administered:	DELAFLOXACIN MEGLUMINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
9.29 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208610s007,208611s006lbl.pdf	300 mg 2 times / day steady-state, intravenous dose: 300 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DELAFLOXACIN MEGLUMINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
7.45 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208610s007,208611s006lbl.pdf	450 mg 2 times / day steady-state, oral dose: 450 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAFLOXACIN MEGLUMINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
21.8 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208610s007,208611s006lbl.pdf	300 mg single, intravenous dose: 300 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DELAFLOXACIN MEGLUMINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
22.7 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208610s007,208611s006lbl.pdf	450 mg single, oral dose: 450 mg route of administration: Oral experiment type: SINGLE co-administered:	DELAFLOXACIN MEGLUMINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
23.4 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208610s007,208611s006lbl.pdf	300 mg 2 times / day steady-state, intravenous dose: 300 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DELAFLOXACIN MEGLUMINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
30.8 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208610s007,208611s006lbl.pdf	450 mg 2 times / day steady-state, oral dose: 450 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DELAFLOXACIN MEGLUMINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
3.7 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208610s007,208611s006lbl.pdf	300 mg single, intravenous dose: 300 mg route of administration: Intravenous experiment type: SINGLE co-administered:		DELAFLOXACIN MEGLUMINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
16% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208610s007,208611s006lbl.pdf	300 mg single, intravenous dose: 300 mg route of administration: Intravenous experiment type: SINGLE co-administered:		DELAFLOXACIN MEGLUMINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
1200 mg single, intravenous Highest studied dose Dose: 1200 mg Route: intravenous Route: single Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/26718605	healthy, 19- 64 years n = 8 Health Status: healthy Age Group: 19- 64 years Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/26718605	Other AEs: Nausea, Gastrointestinal disorders... Other AEs: Nausea (50%) Gastrointestinal disorders (87.5%) Vomiting (75%) Diarrhea (25%) Retching (12.5%) Nervous system disorders (12.5%) Dizziness (12.5%) Feeling hot (12.5%) Respiratory, thoracic and mediastinal disorders (12.5%) Rhinorrhea (12.5%) Skin and subcutaneous tissue disorders (12.5%) Pruritus Sources: https://pubmed.ncbi.nlm.nih.gov/26718605
300 mg 2 times / day multiple, intravenous Recommended Dose: 300 mg, 2 times / day Route: intravenous Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208610s000,208611s000lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: acute bacterial skin and skin structure infections Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208610s000,208611s000lbl.pdf	Disc. AE: Tendinitis, Tendon rupture... AEs leading to discontinuation/dose reduction: Tendinitis (serious) Tendon rupture (serious) Peripheral neuropathy (serious) Myasthenia gravis (serious) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208610s000,208611s000lbl.pdf
300 mg 2 times / day multiple, intravenous Recommended Dose: 300 mg, 2 times / day Route: intravenous Route: multiple Dose: 300 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000MedR.pdf Page: p. 163	unhealthy n = 741 Health Status: unhealthy Condition: acute bacterial skin and skin structure infections Population Size: 741 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000MedR.pdf Page: p. 163	Disc. AE: Hypersensitivity... AEs leading to discontinuation/dose reduction: Hypersensitivity (0.1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000MedR.pdf Page: p. 163
300 \|450 mg\|mg 2 times / day multiple, intravenous\|oral (complex) Recommended Dose: 300 \|450 mg\|mg, 2 times / day Route: intravenous\|oral Route: multiple Dose: 300 \|450 mg\|mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000MedR.pdf Page: p. 163	unhealthy n = 741 Health Status: unhealthy Condition: acute bacterial skin and skin structure infections Population Size: 741 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000MedR.pdf Page: p. 163	Disc. AE: Vomiting, Hypersensitivity... AEs leading to discontinuation/dose reduction: Vomiting (0.1%) Hypersensitivity (0.1%) Urticaria (0.3%) Dermatitis allergic (0.1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000MedR.pdf Page: p. 163

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 781	inhibitor 1767 inducer 389	inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2A6 707 CYP2B6 810 CYP2C8 911 CYP2C19 1478 CYP2E1 882 CYP3A4/5 278 P-gp 1461 BCRP 699 OAT1 599 OAT3 642 OATP1B1 788 OATP1B3 706 BSEP 402 OCT1 512 OCT2 647 UGT1A1 204 UGT1A3 84 UGT1A4 77 UGT1A6 108 UGT1A9 116 UGT2B7 146 UGT2B15 64	UGT1A1 418 UGT1A3 422 UGT2B15 203 OAT1 326 OAT3 339 OCT1 327 OCT2 355 OATP1B1 406 OATP1B3 350 BCRP 561 P-gp 1537	CYP1A2 701 CYP2B6 547 CYP2C19 293 CYP2C8 168

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
BCRP 773	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=16 Page: 16.0	no
BSEP 403	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=16 Page: 16.0	no
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=16 Page: 16.0	no
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=16 Page: 16.0	no
CYP2A6 739	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=16 Page: 16.0	no
CYP2B6 1001	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=16 Page: 16.0	no
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=16 Page: 16.0	no
CYP2C19 1553	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=16 Page: 16.0	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=16 Page: 16.0	no
CYP2C8 965	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=16 Page: 16.0	no
CYP2C8 965	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=16 Page: 16.0	no
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=16 Page: 16.0	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=16 Page: 16.0	no
CYP2E1 970	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=16 Page: 16.0	no
CYP3A4/5 335	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=16 Page: 16.0	no
OAT1 603	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=16 Page: 16.0	no
OAT3 644	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=16 Page: 16.0	no
OATP1B1 803	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=16 Page: 16.0	no
OATP1B3 715	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=16 Page: 16.0	no
OCT1 543	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=16 Page: 16.0	no
OCT2 648	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=16 Page: 16.0	no
P-gp 1650	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=16 Page: 16.0	no
UGT1A1 254	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=36 Page: 36.0	no
UGT1A3 93	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=36 Page: 36.0	no
UGT1A4 80	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=36 Page: 36.0	no
UGT1A6 141	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=36 Page: 36.0	no
UGT1A9 121	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=36 Page: 36.0	no
UGT2B15 64	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=36 Page: 36.0	no
UGT2B7 157	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=36 Page: 36.0	no
CYP2C9 1819	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=16 Page: 16.0	yes
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=16 Page: 16.0	yes	no (co-administration study) Comment: An in vivo DDI study (Study ML-3341-118) of multiple oral doses of delafloxacin (450 mg Q12h) on a single oral dose of midazolam (5 mg) demonstrated no impact on midazolam PK, and minimal impact on 1-hydroxymidazolam PK Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=16 Page: 16.0

Drug as victim

Target	Modality	Activity	Clinical evidence
OAT1 326	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=37 Page: 37.0	no
OAT3 339	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=37 Page: 37.0	no
OATP1B1 406	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=37 Page: 37.0	no
OATP1B3 350	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=37 Page: 37.0	no
OCT1 327	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=37 Page: 37.0	no
OCT2 355	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=37 Page: 37.0	no
UGT1A1 418	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=15 Page: 15.0	yes
UGT1A3 422	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=15 Page: 15.0	yes
BCRP 561	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=37 Page: 37.0	yes	no (co-administration study) Comment: Delafloxacin AUC0-24 values from patients who received P-gp/BCRP inhibitors along with delafloxacin are overlayed with the values from patients who received no P-gp/BCRP inhibitors. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=37 Page: 37.0
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=37 Page: 37.0	yes	no (co-administration study) Comment: Delafloxacin AUC0-24 values from patients who received P-gp/BCRP inhibitors along with delafloxacin are overlayed with the values from patients who received no P-gp/BCRP inhibitors. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=37 Page: 37.0
UGT2B15 203	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=15 Page: 15.0	yes	yes (pharmacogenomic study) Comment: The Cmin data from Study M00-224 seems significantly correlated with UGT2B15*2 genotype. Due to the small sample size (N=27), Applicant concluded that further confirmation is required to elucidate the role of UGT2B15. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000ClinPharmR.pdf#page=15 Page: 15.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000PharmR.pdf#page=85 Page: 85.0

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY10497	https://www.001chemical.com/chem/189279-58-1
AA Blocks	AA002I3C	https://www.aablocks.com/goods/Goods/detail?id=AA002I3C
AK Scientific, Inc. (AKSCI)	X5822	http://www.aksci.com/item_detail.php?cat=X5822
Aaron Chemicals	AR002IV4	http://www.aaronchem.com/189279-58-1
Achemtek	0104-035792	http://www.achemtek.com/189279-58-1
Acorn PharmaTech	ACN-052287	http://www.acornpharmatech.com/
Adooq BioScience	ABT-492	http://www.adooq.com/abt-492.html
Adooq BioScience	A10023	https://www.adooq.com/abt-492.html
Ambinter	Amb22520781	http://www.ambinter.com/reference/22520781
Angene	AGN-PC-0QIQPJ	http://www.angenechemical.com/productshow/AGN-PC-0QIQPJ.html
Ark Pharm	AK232294	http://www.arkpharminc.com/products/189279-58-1.html
Aurum Pharmatech LLC	W-5433	http://www.Aurumpharmatech.com/Product/ProductDetails/W_5433
BLD Pharm	BD360873	http://www.bldpharm.com/products/189279-58-1.html
BOC Sciences	189279-58-1	https://www.bocsci.com/product/delafloxacin-cas-189279-58-1-292324.html
BioCrick	BCC1522	http://www.biocrick.com/Delafloxacin-BCC1522.html
CSNpharm	CSN16520	https://www.csnpharm.com/products/delafloxacin.html
Chem Scene	CS-1478	http://www.chemscene.com/189279-58-1.html
Chemspace	CSSB00020648435	https://chem-space.com/CSSB00020648435
Clearsynth	CS-DS-00004	https://www.clearsynth.com/en/CSDS00004.html
DC Chemicals	DC10458	http://www.dcchemicals.com/product_show-Delafloxacin_ABT_492.html
Excenen	EX-A2331	https://www.excenen.com/searchresultlist.php?id=189279-58-1
Finetech	FT-0697895	http://www.finetechnology-ind.com/prod/detail/pub/189279-58-1.html
LGC Standards	DRE-A12117300AL-100	https://www.lgcstandards.com/US/en/p/DRE-A12117300AL-100
LGC Standards	DRE-C12117300	https://www.lgcstandards.com/US/en/p/DRE-C12117300
Lab Network	LN01342002	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01342002
MedChem Express	HY-14814	https://www.medchemexpress.com/Delafloxacin.html
Molcore	MC10497	https://www.molcore.com/product/189279-58-1
MuseChem	I011446	https://www.musechem.com/product/I011446.html
Selleck Chemicals	S1553	http://www.selleckchem.com/products/ABT-492.html
Sigma-Aldrich	SML1869_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/sml1869?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S525586	http://www.smolecule.com/products/s525586
Sun-shine Chemical	Delafloxacin	http://www.sun-shinechem.com/Details/Delafloxacin/2077/1256037-58-7.html
Synblock Inc	SB16746	http://www.synblock.com/product/189279-58-1.html
THE BioTek	bt-266634	https://www.thebiotek.com/product/inhibitors/bt-266634
eNovation Chemicals	D520374	https://www.enovationchem.com/ProductDetails.asp?ProductID=D520374
eNovation Chemicals	D571807	https://www.enovationchem.com/ProductDetails.asp?ProductID=D571807
eNovation Chemicals	Y0975525	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y0975525
iChemical	EBD246564	http://www.ichemical.com/products/189279-58-1.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs

PubMed

Title	Date	PubMed
Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.	2000 Feb	10639351
New antibiotics for antibiotic-resistant bacteria.	2009 May 28	20948644
Methicillin-resistant Staphylococcus aureus: a pervasive pathogen highlights the need for new antimicrobial development.	2010 Dec	21165342

Patents

Sample Use Guides

In Vivo Use Guide

900mg orally (2 x 450 mg tablets) administered once

Route of Administration: Oral

In Vitro Use Guide

Delafloxacin demonstrated potent in vitro activity against this set of Staphylococcus aureus (MRSA) isolates, with MICs of 0.008-1 mg/L and an MIC(50) and MIC(90) of 0.03 and 0.5 mg/L, respectively.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:36:56 UTC 2023` Edited by `admin` on `Fri Dec 15 16:36:56 UTC 2023`
Record UNII	N7V53U4U4T
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DELAFLOXACIN MEGLUMINE

Official Name

English

D-GLUCITOL, 1-DEOXY-1-(METHYLAMINO)-, 1-(6-AMINO-3,5-DIFLUORO-2-PYRIDINYL)-8-CHLORO-6-FLUORO-1,4-DIHYDRO-7-(3-HYDROXY-1-AZETIDINYL)-4-OXO-3-QUINOLINECARBOXYLATE (SALT)

Common Name

English

1-DEOXY-1-(METHYLAMINO)-D-GLUCITOL 1-(6-AMINO-3,5-DIFLUOROPYRIDIN-2-YL)-8-CHLORO-6-FLUORO-7-(3-HYDROXYAZETIDIN-1-YL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLATE (SALT)

Common Name

English

DELAFLOXACIN MEGLUMINE [MI]

Common Name

English

RX-3341 MEGLUMINE

Common Name

English

ABT-492 MEGLUMINE

Code

English

Delafloxacin meglumine [WHO-DD]

Common Name

English

DELAFLOXACIN MEGLUMINE [USAN]

Common Name

English

DELAFLOXACIN MEGLUMINE [ORANGE BOOK]

Common Name

English

WQ-3034 MEGLUMINE

Common Name

English

Code System Code Type Description

PUBCHEM

11578213